Reference: MD&A (December 31, 2023)

"The impediment to the advancement of apabetalone’s development continues to be financing. We estimate the total cost of the BETonMACE2 study to be on the range of US$80 million. Since our PCC study requires the recruitment of a much smaller patient cohort, as well as shorter treatment and follow-up durations, this trial will cost a small fraction of BETonMACE2. As a result, we expect to be able to move forward with the PCC trial prior to securing a much larger cash infusion. We are in active discussions with multiple parties regarding financing and/or co-development opportunities for apabetalone." (bolding added)

PCC: Post COVID-19 Conditions.

We can only hope: Koo